Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.
XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.
The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.
One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced positive outcomes from its 2022 Annual and Special Meeting of Shareholders on July 20, 2022. Approximately 4.5 million shares were voted, representing 35% of outstanding shares. All proposed resolutions passed with near-unanimous support, including the election of seven directors and the re-appointment of Smythe LLP as auditors. The meeting also saw the approval of a 10% rolling stock option plan, underscoring shareholder confidence in the company's future.
XORTX Therapeutics (NASDAQ: XRTX) announced that it has submitted a request for a scientific advice review to the European Medicines Agency (EMA) regarding its XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD). This submission aims to discuss the program's status and plans for a global phase 3 trial, which follows recent successful R&D activities, including increased oral bioavailability of XRx-008. The company aims to enhance the drug's approval potential, benefiting over 10 million worldwide affected by ADPKD.
XORTX Therapeutics has announced positive topline results from Part 1 of its XRX-OXY-101 Pharmacokinetics Bridging Study, demonstrating a significant increase in oral bioavailability of its proprietary oxypurinol formulations. The trial, which had no adverse events, is a precursor to a planned phase 3 registration trial focused on treating autosomal dominant polycystic kidney disease (ADPKD). Key objectives include determining the optimal formulation and dosing regimen. Part 1 confirmed improved bioavailability and established a pharmacokinetics dataset that aids in future drug development.
XORTX Therapeutics Inc. (NASDAQ: XRTX) has submitted a type B pre-Phase 3 meeting request to the FDA, anticipated in about 70 days. This request follows successful R&D activities for its XRx-008 program targeting autosomal dominant polycystic kidney disease (ADPKD). Key milestones include GMP oxypurinol manufacturing and improved drug formulation. CEO Dr. Allen Davidoff emphasized the meeting's importance for discussing the registration trial protocol and New Drug Application (NDA) for their lead product, which aims to slow renal function decline in ADPKD patients.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced a "Fireside Chat" hosted by CEO Dr. Allen Davidoff on June 22, 2022, at 11 am EST. The session will present updates on innovative therapies aimed at treating progressive kidney diseases, specifically focusing on the company's clinical products: XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for acute kidney injury related to COVID-19. Investors can register for the event through a provided link. XORTX is committed to improving patient quality of life through targeted therapies addressing purine metabolism and uric acid production.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the BIO International Convention 2022, from June 13-16, 2022, in San Diego. CEO Dr. Allen Davidoff will present the company's progress and future plans on June 13 at 2 PM. The event aims to enhance outreach to pharmaceutical partners, with over 30 meetings scheduled. XORTX is developing innovative therapies for progressive kidney disease, including XRx-008 for ADPKD and XRx-101 targeting COVID-19 related acute kidney injury. The company focuses on improving patient quality of life.
XORTX Therapeutics, a late-stage clinical pharmaceutical company, announced its participation in the LD Micro Invitational 2022, taking place from June 7-9, 2022. CEO Dr. Allen Davidoff will present on June 8 at 9:25 am PST, providing updates on the company's progress and future plans. XORTX focuses on innovative therapies for progressive kidney disease, with products in development addressing conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD) and COVID-19 related acute kidney injury. For more details, visit www.xortx.com.
XORTX Therapeutics Inc. has appointed Mr. Anthony Giovinazzo as Chair of the Board of Directors. With over 43 years of experience in the pharmaceutical industry, Giovinazzo aims to bolster XORTX's growth, particularly in advancing the FDA-reviewed drug for kidney diseases into a Phase 3 trial. The company is focusing on developing innovative therapies for progressive kidney disease. Concurrently, XORTX granted stock options to executives, including 150,000 options to Giovinazzo, exercisable at $1.60 over five years.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the H. C. Wainwright Global Investment Conference 2022, held from May 23-26, 2022. Dr. Allen Davidoff, CEO, provided an overview of the company's progress and future plans during the presentation. This event offers a platform to engage with global investors and potential pharmaceutical partners. XORTX is developing innovative therapies aimed at treating progressive kidney diseases, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for acute kidney injury related to COVID-19.
XORTX Therapeutics announces that it has received an all-clear notification from the FDA for its IND application concerning the XRX-OXY-101 bridging pharmacokinetics study, supporting its XRx-008 program aimed at treating autosomal dominant polycystic kidney disease (ADPKD).
This approval is pivotal for advancing clinical trials and securing marketing approval for XRx-008, which targets high serum uric acid levels—a critical factor in kidney disease progression. The ongoing study will provide essential data for future regulatory submissions.
FAQ
What is the current stock price of XORTX Therapeutics (XRTX)?
What is the market cap of XORTX Therapeutics (XRTX)?
What is XORTX Therapeutics Inc.?
What are the main diseases XORTX targets?
Where is XORTX Therapeutics headquartered?
What is TMX-049?
Who are XORTX's strategic partners?
What stage is XORTX Therapeutics in?
What health issues does XORTX aim to address?
What is the focus of XORTX's pipeline?
What are xanthine oxidase inhibitors?
How does XORTX contribute to COVID-19 research?
